Cargando…

Effect of enzyme replacement therapy (ERT) added to Home Mechanical Ventilation (HMV) in Adult Pompe disease

Adult Pompe disease/acid maltase deficiency is an autosomal recessive disorder resulting in accumulation of glycogen in skeletal muscles, leading to myopathy frequently involving respiratory muscles. This involvement can cause respiratory insufficiency that may present as acute hypercapnic respirato...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sayeed, Nadia, Sharma, Pooja, Abdelhalim, Manahil, Mukherjee, Rahul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694595/ https://www.ncbi.nlm.nih.gov/pubmed/26740886 http://dx.doi.org/10.1002/rcr2.136

Ejemplares similares

Enzyme replacement therapy (ERT) in pompe disease
por: Fiumara, Agata
Publicado: (2014)

Starting HMV at home: a reasonable option for many patients?
por: van den Biggelaar, Ries J.M., et al.
Publicado: (2022)

S3.1 Are there ERT defined guidelines for Pompe disease?
por: Toscano, Antonio, et al.
Publicado: (2011)

Successful twin pregnancy in a 38-year-old woman with Pompe disease despite interruption of enzyme replacement therapy (ERT)
por: Tiling, N, et al.
Publicado: (2013)

Enzyme Replacement Therapy (ERT) on Heart Function Changes the Outcome in Patients with Infantile-Onset Pompe Disease: A Familial History
por: Lecis, Marco, et al.
Publicado: (2023)

Hellenic registry of patients with home mechanical ventilation (HR-HMV): profiling sleep Apnea–Hypopnea syndrome patients across Greece
por: Dimitriadis, Vlasios K., et al.
Publicado: (2022)

Safety outcomes and patients’ preferences for home-based intravenous enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond
por: Toscano, Antonio, et al.
Publicado: (2023)

Positive Impact of Home ERT for Mucopolysaccharidoses and Pompe Disease: The Lesson Learnt from the COVID-19 Pandemic
por: Fiumara, Agata, et al.
Publicado: (2023)

Immune Responses and Hypercoagulation in ERT for Pompe Disease Are Mutation and rhGAA Dose Dependent
por: Nayak, Sushrusha, et al.
Publicado: (2014)

CRIM-negative infantile Pompe disease: Characterization of immune responses in patients treated with ERT monotherapy
por: Berrier, Kathryn L., et al.
Publicado: (2015)

Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study
por: Ditters, Imke A. M., et al.
Publicado: (2023)

Enzyme replacement therapy and fatigue in adults with Pompe disease
por: Güngör, Deniz, et al.
Publicado: (2013)

Correction of oxidative stress enhances enzyme replacement therapy in Pompe disease
por: Tarallo, Antonietta, et al.
Publicado: (2021)

Impact of enzyme replacement therapy on survival in adults with Pompe disease
por: Güngör, Deniz, et al.
Publicado: (2013)

Enzyme replacement therapy and antibodies in late-onset Pompe disease
por: Schneider, I., et al.
Publicado: (2014)

Evaluation of muscle biopsy in late-onset GSDII patients before and after enzyme replacement therapy (ERT)
por: Violano, R, et al.
Publicado: (2013)

L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report
por: Rovelli, Valentina, et al.
Publicado: (2022)

Estrogen replacement therapy (ERT) in high-risk cancer patients.
por: Hutchinson-Williams, K. A., et al.
Publicado: (1991)

S2.1 Enzyme replacement therapy (ERT) in Glycogen Storage Disease Type II: the first treatment developed
por: Angelini, Corrado, et al.
Publicado: (2011)

S2.2 Enzyme replacement therapy in the infantile-onset Pompe disease
por: Parenti, Giancarlo, et al.
Publicado: (2011)

Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease
por: Cousens, Leslie P., et al.
Publicado: (2012)

Enzyme Replacement Therapy Can Reverse Pathogenic Cascade in Pompe Disease
por: Meena, Naresh Kumar, et al.
Publicado: (2020)

The impact of interrupting enzyme replacement therapy in late-onset Pompe disease
por: Wenninger, Stephan, et al.
Publicado: (2021)

Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease
por: Sun, Baodong, et al.
Publicado: (2014)

Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction
por: Han, Sang-oh, et al.
Publicado: (2017)

Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction
por: Han, Sang-oh, et al.
Publicado: (2019)

Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients
por: van der Meijden, Jan C., et al.
Publicado: (2018)

Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease()
por: Chien, Yin-Hsiu, et al.
Publicado: (2017)

Standardized nursing management of enzyme replacement therapy for late-onset Pompe disease
por: Tang, Shan, et al.
Publicado: (2021)

Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease
por: Fiege, Lina, et al.
Publicado: (2023)

Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series
por: Lampe, Christina, et al.
Publicado: (2014)

Fabry Disease and the Effectiveness of Enzyme Replacement Therapy (ERT) in Left Ventricular Hypertrophy (LVH) Improvement: A Review and Meta-Analysis
por: Lee, Chung-Lin, et al.
Publicado: (2022)

The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease Fibroblasts
por: Porto, Caterina, et al.
Publicado: (2009)

Improvement of dysphagia in a child affected by Pompe disease treated with enzyme replacement therapy
por: Fecarotta, Simona, et al.
Publicado: (2013)

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease
por: Kanters, Tim A., et al.
Publicado: (2017)

Considerations for evaluating the effectiveness and long-term outcome of enzyme replacement therapy in Pompe disease
por: Cheon, Chong Kun
Publicado: (2019)

Hearing characteristics of infantile-onset Pompe disease after early enzyme-replacement therapy
por: Hsueh, Chien-Yu, et al.
Publicado: (2021)

Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy
por: Güngör, Deniz, et al.
Publicado: (2011)

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
por: Kanters, Tim A, et al.
Publicado: (2014)

Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy
por: Prater, Sean N, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_pt7imh4aisi1as8oi7ck5lct0v